Research from industry analyst GlobalData finds that companies and organizations are continuing to report clinical trial disruptions on account of the ongoing COVID-19 pandemic.
The upset to research and development activities is due to a number of factors, including slower enrollment and suspensions to enrollment, as well as delayed initiation.
Drawing from a survey of key opinion leaders in the pharma industry, researchers found that the primary factor behind the slowdown was slower-than-usual enrollment.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze